Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Oil Prices Rise as Dollar Gains Ahead of Key U.S. Inflation Data 
OpenAI-Microsoft Deal Sets $38 Billion Revenue-Sharing Cap Ahead of Potential IPO 
Asian Currencies Slide as Iran Tensions Boost Dollar and Oil Prices 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
US Stock Futures Slip as Trump Rejects Iran Peace Proposal Amid Rising Middle East Tensions 
Trump Rejects Iran Proposal as Strait of Hormuz Crisis Pushes Oil Prices Higher 
US Auto Industry Urges Trump to Block Chinese EV Market Access 
China Inflation Jumps as Iran Conflict Drives Energy Costs Higher 
Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
Dollar Gains on Safe-Haven Demand as Iran Tensions and Inflation Data Loom 
Kuaishou Stock Jumps on Kling AI IPO Plans and $20 Billion Valuation 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
AcadeMedia Q3 Profit Climbs as International and Adult Education Segments Drive Growth 
China Car Sales Drop Again as EV Export Growth Surges in April 
Asian Stocks Slip as Korea’s KOSPI Tumbles Amid Iran Conflict and Chip Sector Profit-Taking 
Dollar Rises as Strait of Hormuz Crisis Pushes Oil Prices Higher 
Merck & Co. is said to be in advanced talks for the acquisition of Seagen, a biotechnology company focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer.
Fox Business reported that the acquisition deal could be valued at almost $40 billion. The amount could be more as the share price for Seagen is above $200 per share. The deal will help Merck & Co. with its expansion efforts as it adds a new acquisition to its cancer drug portfolio.
Currently, Merck’s highest-selling product is its Keytruda immunotherapy drug. The Rahway, New Jersey pharmaceutical company said that this drug accounted for $17.2 billion worth of its sales last year. As for Seagen, some of its best-selling products include Adcetris, which gathered total sales of $1.4 billion last year.
In any case, while Merck and Seagen are already in the advanced stage of negotiations, it was noted that there is still no assurance that they will be reaching an agreement for the sale of the latter.
Moreover, it was mentioned that any proposed deal in this negotiation is also expected to draw a close look from antitrust regulators. Both Merck and Seagen are still hoping to finally sign an agreement on or before Merck announces its second fiscal-quarter earnings, which has been scheduled for July 28.
Reuters reached out to Merck for comments regarding the acquisition reports, but it was not able to respond to the request immediately. On the other hand, Seagen was said to have declined to comment.
As of Wednesday, July 6, the companies are still discussing a price above $200 per share, and on that day, its closing share price was actually $175. It was added that Seagen has a market capitalization of $32.24 billion based on the records from Refinitiv data.
Meanwhile, industry observers believe that it will make sense if Merck & Co. is able to close its deal with Seagen for $250 or below. This is because this acquisition will definitely boost the company’s business and strengthen its portfolio through the latter’s exclusive cancer immunotherapy drug, Keytruda.
